Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Relaxin-2 protein, human
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Recipient : Relaxera Pharmazeutische
Deal Size : Undisclosed
Deal Type : Partnership
Details : This cooperation agreement designates CBL as the exclusive manufacturing partner for synthetic human relaxin-2 (GMP and non-GMP) and Relaxera as the exclusive sales executive partner for relaxin.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
December 16, 2020
Lead Product(s) : Relaxin-2 protein, human
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Recipient : Relaxera Pharmazeutische
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?
Reset All
